<DOC>
	<DOCNO>NCT00788177</DOCNO>
	<brief_summary>The purpose study assess efficacy pegaptanib ( Macugen® ) neovascular ( exudative ) age-related macular degeneration ( AMD ) first dose administer submacular space instead vitreous body case previous state-of-the-art treatment AMD deem ineffective .</brief_summary>
	<brief_title>Subretinal Macugen® Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Adults age 50 year old neovascular AMD proven FA Patients baseline Have BCVA letter score study eye 20/40 20/320 use ETDRS chart measure 4 meter Snellen equivalent Have CNV lesion type study eye follow characteristic determine fluorescein angiography : Evidence CNV extend geometric center foveal avascular zone . Previous stateoftheart therapy disease deem ineffective follow characteristic give : Loss visual acuity ( 2 Snellen line ) previous 3 month define either OR ≥10 % increase lesion diameter assess fluorescein angiography previous 3 month Ability subject understand character individual consequence clinical trial . Signed date informed consent subject must available start specific trial procedure . Women childbearing potential practicing medically accept contraception ( negative pregnancy test result , serum urine trial entry ) . Subjects present follow criterion include trial : Have relevant ocular disease may associate increase intraocular VEGF level ( namely uveitis , neovascular glaucoma , diabetic retinopathy , diabetic maculopathy , ocular ischemic syndrome , retinal vessel occlusion ) Had previous vitrectomy surgery whatsoever reason Are pseudophakic Have &gt; 50 % area scar whole CNV lesion size see FA Arterial hypertension refractory medical treatment Pregnancy lactation . History hypersensitivity investigational medicinal product drug similar chemical structure excipient present pharmaceutical form investigational medicinal product . Participation clinical trial present clinical trial within last 3 month . Medical psychological condition would permit completion trial signing informed consent . Suspected present ocular periocular infection</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>age-related macular degeneration</keyword>
	<keyword>subretinal injection</keyword>
	<keyword>Pegaptanib</keyword>
	<keyword>Macugen</keyword>
</DOC>